It is hard to imagine that screening for early detection of prostate cancer could be harmful to certain individuals.
Earlier this month the U. S. Preventive Services Task Force recommended that routine prostate cancer screening be discontinued for men who reach 75 years old, though that suggestion is controversial. Prostate cancer is unique because it may […]

continue reading from " Benefits of prostate cancer screening should outweigh risks "

An anti-cancer drug discovered in Auckland has been shown in clinical trials to significantly improve the survival rate of prostate cancer patients.
London-based drug company Antisoma yesterday said two-year survival data from its phase II study of ASA404 in hormone-refractory prostate cancer was 33 per cent with ASA404, and 23 per cent in the control group […]

continue reading from " New drug gives hope to prostate cancer victims "

A team of researchers from the University of Athens has shown that men who work sitting at a desk are more likely to develop prostate cancer than manual workers.
Scientists studied 320 prostate cancer patients and compared them with a similar group of men free from the disease. They looked at whether levels of physical activity […]

continue reading from " Men working in office jobs are much more likely to get prostate cancer "

Cancer researchers in Seattle have concluded that prostate tumors shed tiny but durable strips of genetic material. Existing laboratory tests can identify the genetic molecules, called microRNAs, even if present in only minute amounts in a blood sample. Researchers say that suggests the microRNAs could reveal cancers at their earliest stages.
This is a finding that […]

continue reading from " Genetic scrap found in prostate cancer that could yield a test "

In the August 15, 2008, issue of Clinical Cancer Research, (published online August 12) researchers from the University of Chicago Medical Center report that targeted radiation therapy had completely controlled all signs of cancer in 21 percent of patients who had five or fewer sites of metastatic disease.
The technique could also be applied after chemotherapy […]

continue reading from " Precisely targeted radiation therapy can eradicate limited cancer spread "

The Schneck Medical Center Foundation will again sponsor free prostate cancer screening tests on Sept. 11, 16, and Oct. 7. The screenings will be at Schneck’s Cancer Center on the medical center campus. You must have a scheduled appointment to participate in the free screening
To schedule a prostate cancer screening, call Schneck’s Cancer Center at […]

continue reading from " Schneck to host free prostrate exams "

According to a recent randomized controlled trial published in the August 12 online issue of the Journal of the National Cancer Institute, men with early prostate cancer who undergo radical prostatectomy have a lower rate of death due to prostate cancer than men who are followed without treatment, known as watchful waiting.
The benefit from the […]

continue reading from " Prostatectomy improves outcome of some men with prostate cancer over watchful waiting "

Prostate cancer is suspected when the PSA reading is 4 or higher. The current recommendation is for men aged 50 and older to be offered an annual PSA test, with explanations of its possible risks and benefits. A federal preventive medicine committee this week said that PSA screening should not be done for men aged […]

continue reading from " The standard PSA screening may not be accurate for obese men "

Health Discovery Corporation’s New Molecular Diagnostic Test for Prostate Cancer Successfully Performs at 90% Sensitivity and 97% Specificity in Double-Blind Clinical Trial
Results from Phase I, Phase II and Phase III double-blinded clinical validation studies now completed with prostate tissues obtained from multiple sites, including those tested in collaboration with MD Anderson Cancer Center, demonstrated a […]

continue reading from " New Prostate Cancer Test is Ready for Commercialization "

Testing men for elevated levels of prostate-specific antigen (PSA) in the blood — the gold standard screening test for prostate cancer — may be biased against obese men, whose PSA levels tend to be deceptively low. And this bias may be creating more aggressive cancers in this population by delaying diagnosis, according to a new […]

continue reading from " PSA screening may be biased against obese men, leading to more aggressive cancers "